The immune system, amyloid-β peptide, and Alzheimer's disease
In this review, the case is made that amyloid-β peptide in the brain of patients with Alzheimer's disease is a primary cause of the disease and that immunotherapy directed against this peptide has the potential to halt and/or reverse disease progression. This supposition is supported by the capacity of anti-β-amyloid peptide antibodies to prevent or reverse the disease in mouse models of Alzheimer
